NASDAQ: GILD · Life Sciences · 12 alerts · CIK 882095
Share price
$167.58Close, Nov 16
Market cap
$208B
Shares outstanding
1.24BLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Gilead Sciences, Inc. filings on SEC EDGAR ↗
Gilead Sciences Insider Kelly A. Kramer Sells $1.76M of Stock
Kelly A. Kramer sold 10,376 shares of Gilead Sciences, Inc. at $168.23 to $171.44 a share (average $169.76) in 4 transactions, worth $1.76M in total on Nov 12, 2026. Shares held after the trade: 1,339 (-13.0%).
Gilead Sciences EVP Gen Counsel, Legal & Comp Wettan Keeley M. Cain Sells $558K of Stock
Wettan Keeley M. Cain, EVP Gen Counsel, Legal & Comp, sold 3,399 shares of Gilead Sciences, Inc. at $164.11 a share, worth $558K in total on Nov 6, 2026. Shares held after the trade: 5,360 (-38.8%).
Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $19.7M of Stock
Daniel Patrick O'Day, Chairman & CEO, sold 112,429 shares of Gilead Sciences, Inc. at $175.16 to $175.17 a share (average $175.16) in 2 transactions, worth $19.7M in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 551,683 (-1.7%).
Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $5.33M of Stock
Daniel Patrick O'Day, Chairman & CEO, sold 30,881 shares of Gilead Sciences, Inc. at $167.40 to $175.25 a share (average $172.57) in 6 transactions, worth $5.33M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 551,683 (-0.4%).
Gilead Sciences reported total revenues of $8.3 billion for the third quarter of 2026, driven by $8.29 billion in product sales. Despite a profitable third quarter, the company recorded a net loss of $6.05 billion for the first nine months of 2026, primarily due to $11.3 billion in acquired in-process research and development expenses.
Gilead delivered record 16% base business growth driven by HIV and Oncology, though management faces a significant $1.5 billion revenue headwind in 2028 due to Medicare price setting for Biktarvy.
Gilead Sciences reported third-quarter 2026 financial results, featuring a 13% increase in total product sales to $8.3 billion, driven by strong performance in its HIV portfolio. The company raised its full-year base business revenue guidance for the second time this year, citing robust demand for Biktarvy and HIV prevention products.
“Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business.”
Daniel O’Day, Gilead’s Chairman and Chief Executive Officer
“Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026.”
Daniel O’Day, Gilead’s Chairman and Chief Executive Officer